Glioma Market Insights
A glioma is a central nervous system tumor that arises from glial stem or progenitor cells. Glial cells are a type of cell widely present in the nervous system. Gliomas mainly occur in the brain and, rarely, in the spinal cord.
&nbsp;
<a style="background-color: transparent; color: #1155cc;" href="https://www.delveinsight.com/report-store/glioma-epidemiology-forecast" target="_blank" rel="noopener noreferrer">Glioma Epidemiology</a> Insights (2022)
The Glioma Total incident cases in the 7MM were ~47K cases in 2022
&nbsp;
Glioma Epidemiology Segmentation in the 7MM from 2019 to 2032
<ul>
<li>Total Incident Population</li>
<li>Grade-specific Incident Population</li>
<li>Type-specific Population of High-grade Glioma</li>
<li>Type-specific Population of Low-grade Glioma</li>
<li>Age-specific Population</li>
<li>Glioma Cases Based on Molecular Alterations</li>
</ul>
&nbsp;
<a style="background-color: transparent; color: #1155cc;" href="https://www.delveinsight.com/report-store/glioma-market" target="_blank" rel="noopener noreferrer">Glioma Market</a> Insight (2022)
The Glioma Market size in the 7MM was valued ~USD 1 billion in 2022
&nbsp;
Glioma Market Strengths
<ul>
<li>Rise in the aging population</li>
<li>Improvement in genomics and proteomics</li>
</ul>
&nbsp;
Glioma Market Opportunities
<ul>
<li>Increasing incidence trend</li>
<li>Substantial market opportunity for key players</li>
</ul>
&nbsp;
<a style="background-color: transparent; color: #1155cc;" href="https://www.delveinsight.com/report-store/glioma-pipeline-insight" target="_blank" rel="noopener noreferrer">Glioma Emerging Drugs</a> and Key Companies
<ul>
<li>Regorafenib: Bayer</li>
<li>ONC201: Chimerix</li>
<li>AV-GBM-1: Aivita Biomedical</li>
<li>Enzastaurin (DB-102): Denovo Biopharma</li>
<li>DCVax-L: Northwest Therapeutics</li>
<li>Ofranergene Obadenovec (VB-111): VBL Therapeutics</li>
<li>LAM561 (2-OHOA): Laminar Pharmaceuticals</li>
<li>MEDI4736 (durvalumab): MedImmune</li>
<li>Tasadenoturev (DNX-2401): DNAtrix</li>
<li>ITI-1000 (pp65 DC Vaccine): Immunomic Therapeutics</li>
<li>IGV-001: Imvax</li>
<li>SurVaxM: MimiVax</li>
<li>Berubicin: CNS Pharmaceuticals</li>
<li>GLIOVAC (Sitoiganap): Epitopoietic Research Corporation (ERC)</li>
<li>Lerapolturev + Pembrolizumab: Istari Oncology</li>
<li>SONALA-001 + Exablate 2.0 Device: SonALAsense</li>
<li>VAL-083 (dianhydrogalactitol): Kintara Therapeutics</li>
<li>Pomalidomide: Bristol Myers Squibb</li>
<li>MDNA55: Medicenna Therapeutics</li>
<li>BMX-001: BioMimetix</li>
<li>Lenvatinib &plusmn; Pembrolizumab: Eisai and Merck Sharp &amp; Dohme</li>
<li>Paxalisib (GDC-0084): Kazia Therapeutics</li>
<li>OKN-007: Oblato</li>
<li>Temferon: Genenta Science</li>
<li>EO2401: Enterome</li>
<li>INO-5401+ INO-9012+ LIBTAYO (cemiplimab): Inovio Pharmaceuticals</li>
<li>Selinexor (KPT-330): Karyopharm Therapeutics</li>
<li>VBI-1901: VBI Vaccines</li>
<li>NOX-A12 (Olaptesed Pegol): TME Pharma</li>
<li>Tovorafenib (DAY101): Day One Biopharmaceuticals</li>
<li>Vorasidenib (AG-881): Servier</li>
<li>Eflornithine: Orbus Therapeutics</li>
<li>TVI-Brain-1: TVAX Biomedical</li>
<li>AB-218: AnHeart Therapeutics</li>
<li>BGB-290: Beigene</li>
<li>Mirdametinib: SpringWorks Therapeutics</li>
<li>FT-2102 (Olutasidenib): Forma Therapeutics</li>
<li>Vinblastine + Bevacizumab: Hoffmann-La Roche</li>
<li>Cobimetinib: Hoffmann-La Roche</li>
<li>PEMAZYRE (Pemigatinib): Incyte Corporation</li>
<li>VERZENIO (abemaciclib): Eli Lilly, and others</li>
</ul>

Glioma Market

Glioma Market Infographic

Glioma Symptoms, Treatment, epidemiology, companies, drugs, infographic is a short guide to understand the problem and market landscape